Weekly Recap: Q2 revenue rise, higher FY guide and GSP T1D 3plex launch
Revvity, Inc. (NYSE:RVTY) shares hit a 52—week high after Q2 pro forma revenue of $730M and a raised FY guide to $2.83B—$2.86B, while the company expanded diagnostics with the SuperFlex prenatal test, automated T—SPOT.TB development and the CE—IVDR GSP T1D 3plex for pediatric screening.Previous Wee…